



Pharmacy Formulary Updates for October 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status October 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO- MA
Tramadol ER	\$3.65;PA;QL
Fentanyl Patch	\$3.65;PA;QL
Morphine Sulfate ER	\$3.65;PA;QL
Oxycontin	\$3.65;PA;QL
Supprelin LA	MB/RX;PA;SP
Ferriprox 1000mg	\$3.65;PA
Mavenclad	\$3.65;PA;SP;QL
Cablivi	\$3.65
Piqray	\$3.65;PA;SP
Spravato	MB;PA
Zulresso	MB;PA
Apadaz	\$3.65;PA;QL
Aubagio	\$3.65;SP;QL
Gilenya	\$3.65;SP;QL
Tecfidera	\$3.65;SP;QL
Mesalamine DR 1.2gm	\$3.65
Vascepa	\$3.65;PA
Duavee	\$3.65

Key

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- MB/RX:** Drug can be dispensed through Medical Benefit or Prescription Benefit
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy